KaNDy Therapeutics presents new compelling data with lead candidate NT-814 at The North American Menopause Society 2018 Annual Meeting

~ Treatment with NT-814 resulted in immediate improvements in bothersome post-menopausal symptoms~ ~ Phase Ib/IIa data showed rapid and significant reductions in the frequency and severity of hot [...]

KaNDy Therapeutics successfully raises £25 million in a Series C financing. Funding to advance a breakthrough non-hormonal treatment for symptoms of the menopause, into a Phase 2b study in Q4 2018

Stevenage, UK, 29 August 2018 – KaNDy Therapeutics, a clinical-stage Women’s Health company, today announces it has successfully closed a Series C financing round, raising £25 million from new US [...]

Dr Mike Trower CSO KaNDy Therapeutics will present at the 9th International Congress of Neuroendocrinology, Toronto, Canada July 15th – 18th, 2018

Mary Kerr CEO NeRRe Therapeutics and Managing Director KaNDY Therapeutics will be presenting a case study on the “Demerger of NT-814 to KaNDY Therapeutics, Business Model Innovation and Value Creation; 7TH LSX CEO FORUM , Wednesday 27th June 2018, CMS, Cannon Place, 78 Cannon St, London EC4N 6AF

KaNDy Therapeutics and NeRRe Therapeutics announce the appointment of Jo Craig as Head of Chemistry Manufacturing and Controls

Stevenage, UK, 21 June 2018 – KaNDy Therapeutics, a UK clinical-stage biotech company, today announces the appointment of Jo Craig as Head of Chemistry Manufacturing and Controls for both KaNDy [...]

Contact Us

Please fill out the form to get in touch with us.

Not readable? Change text. captcha txt